All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Topical Antiseptic Bundle for Decreasing Surgical Site Infection after Head Neck Cancer Surgery: Peri-operative Effects on the Oral Microbiome
A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or without Adjuvant Docetaxel
A Phase 1 Study to Evaluate The Effect Of Hepatic Impairment On The Pharmacokinetics And Safety Of Lorlatinib In Advanced Cancer Patients
A Phase I/II Trial of Pazopanib Alternating with Bevacizumab in Treatment-Naïve Metastatic Clear Cell Renal Cell Carcinoma Patients
Randomized Phase II/III trial of adjuvant radiation therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in pathologic high-risk Squamous Cell Cancer of the head and neck
Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST chemo-IO
A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPCA
A Phase 2 Study of CAbozantinib in combination with AtezolizumaB as NeoAdjuvant Treatment for Muscle-Invasive BladdEr Cancer (ABATE)
increase the chances of keeping you cancer free. Researchers will also look at the good and
bad effects of the combination including side effects.